Northland Starts Aridis Pharmaceuticals (ARDS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/3/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's revenue misses estimates as AI chip race heats up, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Alphabet plans $80 billion equity raise to fund AI infrastructure expansion, Berkshire Hathaway to invest $10 billion
- Alphabet plans $80 billion raise for AI, backed by Buffett’s Berkshire
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Laidlaw Starts Aridis Pharmaceuticals (ARDS) at Buy
September 10, 2018 6:41 AM EDTLaidlaw analyst Francois Brisebois initiates coverage on Aridis Pharmaceuticals (NASDAQ: ARDS) with a Buy rating and a price target of $23.00.
The analyst come sout Buy rated and his target is based on SOTP analysis with AR-301 valued at $13/share, AR-105 at... More
Cantor Fitzgerald Starts Aridis Pharmaceuticals (ARDS) at Overweight
September 10, 2018 5:06 AM EDTCantor Fitzgerald analyst Louise Chen initiates coverage on Aridis Pharmaceuticals (NASDAQ: ARDS) with a Overweight rating and a price target of $25.00.
The analyst comments "ARDS is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening... More
